Related by context. All words. (Click for frequent words.) 71 ONTARGET 67 PRoFESS 67 Ovarian Cancer Screening 66 Phase IIB 66 multicenter randomized controlled 65 RE LY ® 65 Phase Ib clinical 65 multicenter randomized clinical 65 Multicenter Automatic Defibrillator Implantation 65 BCIRG 65 phase IIa clinical 65 multicentre randomized 64 LUX Lung 64 EURIDIS 64 Prostate Cancer Prevention 64 RE MODEL 64 ACCORD Lipid 64 Phase IIIb clinical 63 CLARITY TIMI 63 GISSI 63 placebo controlled clinical 63 Randomized Evaluation 63 AIM HIGH 63 Valsartan 62 Phase IIIb 62 ENESTnd 62 multicentre randomized controlled 62 RE LY 62 DAPT 62 Spine Patient Outcomes 62 placebo controlled Phase 62 randomized Phase IIb 62 FORTIS M 62 LUMINATE 62 phase IIb clinical 62 BRIM3 61 Phase III VISTA 61 HYVET 61 HPTN 61 MADIT 61 ToGA 61 Randomised 61 relapsed MM 61 Phase Ib II 61 Betaferon ® 61 UPLYSO 61 EchoCRT 61 National Emphysema Treatment 61 CATIE AD 61 STRIDE PD 61 Acute Decompensated Heart Failure 61 PFO migraine 61 phase IIIb 61 Intervention Effectiveness 61 Phase III psoriasis 60 TRANSCEND 60 double blinded randomized 60 ACRIN 60 WHI Dietary Modification 60 Pivotal Phase III 60 EVEREST II 60 ISEL 60 Pivotal Trial 60 MYDICAR 60 tesmilifene 60 RhuDex 60 ECASS 60 Randomized controlled 60 CBLC# 60 IFN α 60 ASSERT 60 Phase III Pivotal 60 phase IIa 60 Glypromate 60 brivaracetam 60 Phase III randomized controlled 59 ASPIRE HIGHER 59 HuMax EGFr 59 PRE SURGE 59 subanalysis 59 fosbretabulin 59 Randomized Phase 59 Aggressive Reduction 59 canakinumab 59 CCX# B 59 placebo controlled Phase III 59 TG MV 59 CIMZIA TM certolizumab pegol 59 CIMZIA TM 59 fostamatinib 59 randomized multicentre 59 BRIM2 59 Arimidex Tamoxifen Alone 59 Initiate Phase II 59 AOD# [002] 59 Asthma Intervention 59 Intervention Trial GAIT 59 phase IIb 59 Prospective Randomized 59 Catena ® 59 TMC# C# 59 Serious Adverse Events 59 PRECiSE 59 Degarelix 59 ADMIRE HF 59 multicenter randomized placebo controlled 59 Prostate Lung Colorectal 59 relapsing multiple sclerosis 59 ACTIVE W 59 Ozarelix 58 Prostate AdenoCarcinoma Treatment 58 VESTASYNC 58 Dasatinib 58 DU #b 58 EndoTAG TM -1 58 PREVENT IV 58 multicenter Phase 58 Aflibercept 58 multicenter clinical 58 Cloretazine 58 NATRECOR R 58 AEGR 58 Phase III HEAT 58 Investigator Initiated 58 Randomized Clinical Trial 58 HCV RESPOND 2 58 ILLUMINATE 58 multicenter placebo controlled 58 Trandolapril 58 Sibutramine Cardiovascular Outcomes 58 Apixaban 58 Phase IIA 58 prospective randomized multicenter 58 tipranavir 58 riociguat 58 SPIRIT FIRST 58 Phase IIb kidney transplant 58 abacavir Ziagen 58 Initiate Phase 58 Alfimeprase 58 Acute Ischemic Stroke 58 axitinib 58 Severe Sepsis 58 Randomized Phase III 58 Stenting Trial CREST 58 APEX PD 58 CAMMS# 58 PreCISe 58 Pivotal Phase 58 SCD HeFT 58 TAXUS ATLAS 58 Phase III placebo controlled 58 randomized controlled clinical 58 sunitinib malate 58 Multicenter 58 Candesartan 58 ENDEAVOR III 58 Meets Primary Endpoint 58 CHAMPION PCI 58 phase III ACCLAIM 58 multicenter Phase II 58 Refractory Angina 58 APTIVUS 58 Tanespimycin 58 Pivotal Phase II 58 ARIXTRA 58 Current Controlled Trials 58 Diabetes ACCORD 58 Infarct 58 Pemetrexed 58 Phase Ib IIa 58 JAK inhibitor 58 Phase III ThermoDox 58 Ridaforolimus 58 Dacogen decitabine 58 Multicenter Randomized 58 REALITY Trial 58 treatment naive genotype 58 confirmatory clinical 58 Cetrorelix 57 oral FTY# 57 Long Lesion 57 CALGB 57 NSABP 57 Multiple Ascending Dose 57 NO# [002] 57 MERLIN TIMI 57 Edge STudy 57 Phase Ib Clinical Trial 57 ancrod 57 Adenoma Prevention 57 fenretinide 57 YONDELIS 57 elotuzumab 57 PROactive study 57 mITT population 57 Lung Screening 57 Initiated Phase 57 Patient Outcomes 57 Malignant Melanoma 57 prospective randomized placebo 57 multicentre prospective 57 TRITON TIMI 57 EOquin TM 57 CALGB # [002] 57 prospective multicentre 57 multicenter phase 57 cathepsin K inhibitor 57 YERVOY 57 Phase #b/#a clinical 57 HuLuc# 57 SPIRIT IV 57 GSK# [001] 57 CHARM Added 57 placebo controlled randomized 57 Val HeFT 57 Phase 1b clinical 57 ENGAGE AF TIMI 57 TRANSFORMS 57 MIST II 57 ADVANCE PD 57 Randomized Phase II 57 prospective randomized controlled 57 Pirfenidone 57 Phase 1a clinical 57 Traficet EN 57 PSMA ADC 57 prospective multicenter randomized 57 Phase 2b kidney transplant 57 Phase #b/#a 57 ZACTIMA 57 Virulizin R 57 darapladib 57 Vicriviroc 57 Controlled Trial 57 stated Michelle Berrey 57 CAPRIE 57 Delcath Phase III 57 methylnaltrexone 57 ELCAP 57 CERVARIX 57 tocilizumab 57 dose escalation clinical 57 Serious Adverse Event 57 COPERNICUS 57 Pooled Analysis 57 prucalopride 57 Triolex 57 Therapeutic Arthritis 57 Phase IIb III 57 ATACAND 57 Amrubicin 57 STENT 57 afatinib 57 assessing T DM1 56 prospective multicenter 56 recurrent glioma 56 Sorafenib HCC Assessment 56 ELND# 56 Telcyta 56 Oral Fingolimod 56 tanespimycin 56 Bicifadine 56 FDA defined valvulopathy 56 ENDEAVOR IV 56 ataluren 56 multicenter randomized 56 lumiliximab 56 iPrEx 56 randomized blinded 56 Phase #/#a 56 randomized multicenter 56 randomized controlled Phase 56 Onconase 56 Phase 2b monotherapy 56 designated HVTN 56 Neoadjuvant 56 BIBW 56 pertuzumab 56 ADHERE 56 Lucanix 56 MAGE A3 ASCI 56 MICARDIS ® 56 Phase III randomized 56 TASKi3 56 CONQUER OB 56 Acute Stroke 56 Glufosfamide 56 ARCALYST ® rilonacept 56 ROCKET AF 56 Ranolazine 56 IRESSA 56 Adjuvant Breast Cancer 56 NCT# ClinicalTrials.gov 56 AA Amyloidosis 56 thorough QT 56 GOUT 56 Intervention Effectiveness CATIE 56 NSABP B 56 Hepatotoxicity 56 Intervention Trial 56 BAL# [002] 56 AZOR 56 Exelixis XL# 56 clinical pharmacology studies 56 ExTRACT TIMI 56 Cardiotoxicity 56 AVADO 56 SNT MC# 56 Rilonacept 56 multicenter prospective 56 Sym# 56 teriflunomide 56 Pafuramidine 56 NCCTG N# 56 Angiox R 56 Actimmune ® 56 Golimumab 56 AZILECT R 56 Xanafide 56 HCV SPRINT 56 RELOVAIR ™ 56 Diabetic Nephropathy 56 multicentre randomized double 56 Etanercept 56 IMPACT IMmunotherapy 56 randomized Phase III 56 PegIFN RBV 56 RTOG 56 ORAL Sync 56 CYPHER Stent 56 Ovarian PLCO Cancer 56 ADAGIO study 56 Pulmonary Arterial Hypertension 56 Sorafenib 56 Randomized Controlled 56 OLYMPIA registry 56 Randomized Study 56 Fabry Disease 56 RE COVER 56 Cloretazine ® 56 iPrEx study 56 investigational protease inhibitor 56 TLK# 56 ARCOXIA 56 MGd 56 Androxal TM 56 MADIT II 56 First Patient Enrolled 56 dose escalation phase 56 keloid scarring 56 NEVO RES 56 APPRAISE 56 Cethromycin 56 Tyrima 56 active comparator 56 CIMZIA ™ 56 ularitide 56 StemEx 56 ACZ# 56 CUSTOM II 56 Dalbavancin 56 COPAXONE R 56 TRO# 56 CARE HF 55 GAMMAGARD 55 Multicenter Phase 55 Blinatumomab 55 TQT 55 Natalizumab 55 CLL8 55 Safinamide 55 mycophenolate mofetil 55 Aggrenox ® 55 REMEDIAL II 55 satraplatin Phase 55 PRESEPT 55 BLP# Liposome Vaccine 55 Phase III 55 PERSEUS 55 Teplizumab 55 Phase III Clinical Trials 55 reslizumab 55 Lung Cancer Trial 55 Protease Inhibitors 55 Azedra 55 BARI 2D 55 decitabine 55 blind randomized controlled 55 BAY #-# 55 Phase III Clinical Trial 55 Epirubicin 55 Vidofludimus 55 REMINYL ® 55 Daclizumab 55 Novartis Zometa 55 Cholesterol Levels SPARCL 55 GW# [003] 55 ocrelizumab 55 Elagolix 55 Proellex TM 55 aclidinium bromide 55 blinded randomized placebo controlled 55 PD2i ® 55 Placebo controlled 55 Combination REOLYSIN R 55 oral ridaforolimus 55 Ataluren 55 Hepatitis C Antiviral 55 Medtronic CoreValve 55 recurrent glioblastoma multiforme 55 Alemtuzumab 55 phase Ib 55 Mylotarg 55 IIa clinical 55 COPAXONE ® 55 Saxagliptin 55 ATTRACT 55 CURRENT OASIS 7 55 Vascugel 55 TASKi2 55 Advagraf 55 RIO Lipids 55 ACTEMRA TM 55 Tesmilifene 55 EDEMA3 55 Diabetic Neuropathy 55 blinded randomized 55 PLCO 55 Mycophenolate Mofetil 55 ISTODAX 55 SUTENT ® 55 ASA# 55 TELCYTA 55 landmark ATHENA 55 sunitinib 55 multicenter randomized Phase 55 Phase Ia 55 Dual Antiplatelet Therapy 55 Left Ventricular Dysfunction 55 Randomized Double blind 55 NOXAFIL 55 PROMACTA 55 TMC# [002] 55 masked placebo controlled 55 Sipuleucel T 55 Enzyme Replacement Therapy 55 Phase 2b Clinical Trial 55 mertansine 55 tipifarnib 55 alteplase 55 CLARITY study 55 selective androgen receptor modulator 55 Follicular Lymphoma 55 Decompensated Heart Failure 55 CoFactor 55 olaparib 55 ENDEAVOR II 55 Teriflunomide 55 ATL# [001] 55 TAXUS TM 55 everolimus eluting stent 55 EORTC 55 SPIRIT III 55 Phase IIa clinical 55 controlled multicenter 55 lomitapide 55 Investigational Drug 55 prostate cancer AIPC 55 PRTX 55 PRADAXA 55 Raptiva ® 55 Double Blind Randomized 55 NN# [001] 55 IMPACT DCM clinical 55 registrational Phase 55 photoprotective drug 54 rFVIIIFc 54 Prospective Multicenter 54 Zenvia Phase III 54 IMC #B 54 acyclovir Lauriad R 54 Panitumumab 54 SUTENT 54 HoFH 54 randomized clinical 54 Losartan 54 Randomized Double Blind 54 INCB# [003] 54 Ophena TM 54 Gastric Cancer 54 ORMD 54 longitudinal cohort study 54 synthetic retinoid 54 Schizophrenia Treatment 54 ONCONASE R 54 HuMax CD# 54 Digital Mammographic Imaging 54 Lp PLA 2 54 Epanova 54 Bezielle 54 XYOTAX TM 54 Apaziquone 54 TroVax 54 Efficacy Trial 54 Prolongs Survival 54 Phase III registrational 54 AVERROES 54 Prospective Randomized Double 54 OvaRex ® MAb 54 Stent Thrombosis 54 EMPHASIS HF trial 54 Vectibix monotherapy 54 Phase 1a 54 Topline Results 54 Therapy Evaluation 54 Tavocept 54 ELONVA 54 neratinib 54 NICE SUGAR 54 Enzastaurin 54 posaconazole 54 Subgroup analysis 54 Canvaxin 54 atrasentan 54 TAXUS V 54 Epratuzumab 54 Motesanib 54 glufosfamide 54 HDAC Inhibitor 54 Initiates Phase III 54 Clinicaltrials.gov 54 dabigatran etexilate 54 LCP AtorFen 54 Velcade bortezomib 54 Aplidin 54 BETAS 54 UVIDEM 54 bardoxolone 54 Cinquil 54 Relapsing Remitting Multiple Sclerosis 54 Nilotinib 54 ZYBRESTAT fosbretabulin 54 double blinded placebo 54 Allovectin 7 R 54 tesofensine 54 Aptivus ® 54 eprotirome 54 multicentre 54 Pivotal Clinical Trial 54 EMPHASIS HF 54 Phase Forward InForm 54 Aclidinium 54 Cardiac Allograft Rejection 54 Antiangiogenic 54 PhG alpha 1 54 Aplidin R 54 viral kinetics 54 ISIS # 54 trastuzumab emtansine T DM1 54 invasive candidiasis 54 Quinamed 54 evaluable subjects 54 ALLHAT 54 XL# SAR# 54 pharmacokinetic PK study 54 Vascugel ® 54 Zarnestra 54 rilonacept 54 Double Blind Placebo 54 Oral Insulin Capsule 54 Desmoteplase 54 APTIVUS r 54 ongoing Phase 1b 54 NeuroStar TMS Therapy 54 blinded placebo controlled 54 ofatumumab HuMax CD# 54 Myocardial Infarction 54 Liprostin 54 goserelin 54 MYDICAR ® 54 lorcaserin Phase 54 BRAF inhibitor 54 Keryx Biopharma 54 Eculizumab 54 PRIALT 54 VADT 54 ganetespib 54 Cardiovascular Outcomes 54 IL# PE#QQR 54 forodesine 54 dexpramipexole 54 budesonide foam 54 Medidata Designer 54 Hepatocellular Carcinoma 54 FDA Investigational Device 54 Dextofisopam 54 R#/MEM # 54 mg/m2 dose 54 Fracture Intervention Trial 54 microplasmin Phase III 54 prospectively defined 54 eltrombopag 54 VICTOR E1 54 Temsirolimus 54 docetaxel Taxotere ® 54 NP2 Enkephalin 54 Investigational Treatment 54 ON #.Na 54 Mipomersen 54 standard chemotherapy regimen 54 Corgentin 54 reboxetine 54 randomized multicenter trial 54 multicenter multinational 54 Scandinavian Cardiac Outcomes 54 DCCR 53 Alpha Tocopherol Beta Carotene 53 CUSTOM III 53 ATAC Arimidex Tamoxifen Alone 53 Exherin TM 53 Virulizin ® 53 mapatumumab 53 epoetin alpha 53 randomized controlled multicenter 53 STOP AF 53 galiximab 53 Carotid Revascularization Endarterectomy vs. 53 Dacogen injection 53 vorinostat 53 Truvada tablets 53 mg BID dose 53 XIENCE V PROMUS Stent 53 Vorapaxar 53 CLORETAZINE TM VNP#M 53 HeFT 53 Screening Trial 53 IFN alfa 53 lupus nephritis 53 ENDEAVOR clinical 53 regorafenib 53 AZILECT ® 53 Multi MERCI 53 ritonavir boosted 53 Silodosin 53 Phase 2a trial 53 Combination Treatment 53 Multicenter Trial 53 Oxypurinol 53 randomized multicenter Phase III 53 Diabetic Macular Edema 53 Phase III Psoriasis 53 SYMMETRY trial 53 comparator arm 53 EXCITE 53 plerixafor 53 NCIC CTG 53 Glivec imatinib 53 Pradefovir 53 KRN# 53 Teriparatide 53 virologic response 53 orBec 53 Severe Asthma 53 Stenting Trial 53 INT# [002] 53 Gynecologic Oncology Group 53 custirsen 53 abiraterone acetate 53 Pivotal Study 53 MEND CABG 53 RhuDex ® 53 mRCC 53 NABTT 53 pivotal bioequivalence 53 ABSORB trial 53 PRT# 53 Clinical Outcome 53 doxorubicin docetaxel 53 Archexin 53 COR Diabetes 53 lexidronam injection 53 Urocortin 2 53 OHR/AVR# 53 metastatic malignant 53 Elvitegravir 53 PROTEGE 53 Nanobody 53 metastatic hormone refractory 53 Trial NLST 53 Diamyd ® 53 pharmacokinetic characteristics 53 OvaRex MAb 53 Cloretazine R VNP#M 53 ANCHOR trial 53 pegylated interferon alfa 2b 53 eplerenone 53 Medidur TM FA 53 HF ACTION 53 tramiprosate Alzhemed TM 53 ATL/TV# 53 E1 INT TM 53 relapsing remitting MS RRMS 53 Curaxin CBLC# 53 Glucosamine chondroitin Arthritis 53 LibiGel Phase III 53 refractory prostate cancer 53 Ziprasidone 53 Carfilzomib 53 Dendreon Provenge 53 viral kinetic 53 Atrasentan 53 Cethrin 53 PARP inhibitor 53 Ischemic 53 pradefovir 53 phase IIb trial 53 Ophena 53 Phase IIb Trial 53 ABSORB clinical 53 DAPT Study 53 Evoltra 53 Deforolimus 53 Ocrelizumab 53 recurrent malignant glioma 53 ALSYMPCA 53 receptor tyrosine kinase inhibitor 53 Parathyroid Hormone 53 NLX P# 53 PROCHYMAL 53 multicenter randomized double 53 trials RCTs 53 Sapacitabine 53 IMA# 53 Valdoxan 53 crizotinib PF # 53 paclitaxel poliglumex 53 R#/MEM 53 Phase IIb clinical 53 Elocalcitol 53 multicenter Phase III 53 oral deforolimus 53 SVR# 53 Phase Ib 53 Corlux 53 PF # [001] 53 Multicentre 53 ascending dose 53 AVOREN 53 Clolar ® 53 phase Ib clinical 53 Aurora Kinase 53 Melphalan 53 Pimavanserin 53 Recurrent Stroke 53 ixabepilone 53 INCB# [001] 53 SWOG 53 Adjuvant Chemotherapy 53 PF # [002] 53 EGFR HER2 53 Hepatocellular Carcinoma HCC 53 TAXUS IV 53 glucokinase activator 53 BioNumerik 53 Estradiol 53 Plicera 53 LAF# 53 masitinib 53 ximelagatran 53 EDEMA4 53 Patient Registry 53 AP# [003] 53 Phase 2b clinical 53 atacicept 53 desvenlafaxine 53 DASISION 53 depsipeptide 53 dacetuzumab 53 evaluating tivozanib 53 Adult Stem Cell Therapy 53 Phase 2b Trial 53 ZYBRESTAT TM 53 Relieve Depression 53 Renal Cancer 53 Aortic Stenosis 53 interferon gamma 1b 53 Zemplar Capsules 53 Phase 2b 53 carotid artery stenting CAS 53 Ancrod 53 ROTATEQ 53 REACH Registry 53 Novel Oral 53 Vitaxin 53 Breast Density 53 confirmatory Phase 53 Advaxis Phase 53 valopicitabine 53 gastrointestinal stromal tumors GIST 53 Related Mortality 53 BNC# 53 PREOS R 53 observational cohort 53 Percutaneous Tibial Nerve Stimulation 53 Subgroup Analysis 52 neurologic progression 52 RSD# oral 52 prospective nonrandomized 52 relapsed refractory multiple myeloma 52 darunavir ritonavir 52 QVA# 52 bendamustine 52 Prosaptide 52 vandetanib 52 MADIT CRT 52 vidofludimus 52 Decitabine 52 NCCTG 52 Biomarker Study 52 Denufosol 52 CHAMPION PLATFORM 52 MIRCERA 52 edoxaban 52 Long Term Efficacy 52 cluster randomized controlled 52 recurrent VTE 52 Onconova 52 HOPE TOO 52 NTx 52 phase IIb III 52 Phase 2a clinical 52 Plenaxis TM 52 PreCISe study 52 DXL# 52 Laquinimod 52 Radiation Therapy Oncology 52 Phase 2b trial 52 Rasilez Tekturna 52 Clinical Antipsychotic Trials 52 Oral Mucositis 52 Dapagliflozin 52 rNAPc2 52 HuMax 52 FOLOTYN ® 52 Allergic Rhinitis 52 Viralytics 52 controlled multicenter Phase 52 lintuzumab 52 refractory angina 52 Critical Limb Ischemia CLI 52 alvespimycin 52 CVac 52 International Verapamil SR 52 LymphoStat B 52 #:# randomization 52 Neoadjuvant Chemotherapy 52 Granulocyte Colony Stimulating Factor 52 platelet inhibitor 52 OncoVEX GM CSF 52 Phase III clinical 52 Neupogen ® 52 SEPET TM 52 Women Ischemia Syndrome 52 desvenlafaxine succinate 52 Polyp Prevention Trial 52 pharmacodynamic effects 52 Phase III Trials 52 Daptomycin 52 Non Alcoholic Steatohepatitis 52 hepatitis C HCV 52 APF# Phase 52 farletuzumab 52 Phase III randomized placebo 52 nonrandomized 52 NYHA Class II 52 subcutaneously administered 52 randomized Phase 2b 52 EOquin 52 diabetic neuropathic pain 52 Myoblast 52 MoxDuo TM IR 52 catheter occlusion 52 LCP Tacro 52 Phase 2a preventative 52 II Clinical Trial 52 Cimzia ® certolizumab pegol 52 GENASIS clinical 52 OBPM 52 rALLy clinical trial 52 Uterine Cancer 52 PEG Interferon lambda 52 Vernakalant 52 Androxal 52 PEG SN# 52 ISTODAX ® 52 antibody MAb 52 Congestive Heart Failure 52 Eluting Stent 52 XmAb# 52 nab paclitaxel 52 pivotal Phase III 52 pharmacokinetic PK profile 52 Acute Heart Failure 52 Viprinex TM 52 Proxinium TM 52 OVATURE 52 Trial PCPT 52 ruboxistaurin 52 SNT-MC#/idebenone 52 trastuzumab DM1 T DM1 52 Rheumatoid Arthritis RA 52 TASQ 52 SCH # 52 Anturol TM 52 trabectedin 52 ORACLE MS 52 Advanced Renal Cell 52 Early Lung Cancer 52 Phase 1b 52 pomalidomide 52 Diamyd Medical Diamyd 52 randomized discontinuation 52 ELACYT 52 beta 1a 52 HQK 52 elacytarabine 52 elesclomol 52 Preclinical Study 52 Nonalcoholic Fatty Liver Disease 52 azilsartan medoxomil 52 Rotigotine 52 Bapineuzumab 52 tafamidis 52 Antiplatelet Therapy 52 clazosentan 52 Metastatic Colorectal Cancer 52 donepezil Aricept 52 EINSTEIN DVT 52 VEGF Trap 52 huC# DM4 52 OPAXIO 52 Hepatitis C Infection 52 UKPDS 52 Clinical Trial Data 52 Pivotal Trials 52 Recurrent Glioblastoma 52 p# biomarker 52 Symadex 52 HORIZONS AMI trial 52 pain palliation 52 Phenoptin 52 Pazopanib 52 AIR2 Trial 52 CombAT 52 Glatiramer acetate 52 Phase Ib study 52 Study Evaluating 52 NeuroSTAT ® 52 TAXUS Stent 52 Bronchitol 52 Coronary Revascularization 52 CIPN 52 cangrelor 52 Iloperidone 52 Raptiva R 52 Yondelis ® 52 blind multicenter 52 Randomised Controlled Trial 52 Allogeneic 52 6R BH4 52 conjugated estrogens 52 Cogentus 52 Acute Coronary Syndrome 52 immunotherapeutic vaccine 52 Plasmin 52 temsirolimus 52 Chronic Heart Failure 52 TEMSO 52 Myelodysplastic Syndrome MDS 52 Bendamustine 52 ibandronate 52 Ushercell 52 MoxDuo IR 52 evaluating REVLIMID 52 Teysuno 52 ERSPC 52 velafermin 52 aleglitazar 52 Hsp# Inhibitor 52 secondary efficacy endpoints 52 Talactoferrin 52 dose escalation Phase 52 Lu AA# 52 Phase Ib IIa clinical 52 Faropenem 52 pharmacokinetic PK 52 CYPHER R Sirolimus eluting 52 Tarceva erlotinib